Aop:134
Status
This is a legacy representation of this AOP. Please see the current version here:
AOP Title
Authors
Mary Gilbert, National Health and Environmental Effects Research Laboratory, US EPA, RTP, NC USA <gilbert.mary@epa.gov>
Anna Price, European Commission Joint Research Centre, Institute for Health and Consumer Protection, Ispra, Italy <anna.price@jrc.ec.europa.eu>
Kevin Crofton, National Center for Computational Toxicology, US EPA, RTP, NC USA <crofton.kevin@epa.gov>
Status
Please follow the link to snapshots page to view and create Snapshots of this AOP.
Under development: Do not distribute or cite.
This AOP page was last modified on 12/11/2016.
Click here to show/hide revision dates for related pages
Page | Revision Date/Time |
---|
Abstract
This AOP describes one adverse outcome that results from the inhibition of the sodium iodine symporter (NIS) during mammalian development. Inhibition of NIS, the molecular-initiating event (MIE), results in decreased iodine uptake, decreased thyroidal iodine content, subsequent decreased synthesis of thyroid hormones (THs), and reduction in circulating levels of THs. THs are essential for normal human brain development, both prenatally and postnatally. Therefore, chemicals that interfere with TH synthesis have the potential to cause TH insufficiency that may result in adverse neurodevelopmental effects in offspring. This AOP includes changes in brain TH concentrations and subsequent impacts on hippocampal development that lead to declines in cognitive spatial behavior. The weight of evidence for this AOP is strong. And, while there are currently computational quantitative models that can predict serum TH levels from NIS inhibition, there is currently a lack of quantitative understanding of the degree of serum TH disruption that leads to the adverse outcome.
Background (optional)
Summary of the AOP
Please follow link to widget page to edit this section.
If you manually enter text in this section, it will get automatically altered or deleted in subsequent edits using the widgets.
Molecular Initiating Event
Molecular Initiating Event | Support for Essentiality |
---|---|
Na+/I- symporter (NIS), Inhibition | Strong |
Key Events
Adverse Outcome
Adverse Outcome |
---|
Cognitive Function, Decreased |
Relationships Among Key Events and the Adverse Outcome
Network View
Cytoscape Web will replace the contents of this div with your graph.
Click nodes or edges.
Life Stage Applicability
Life Stage | Evidence | Links |
---|---|---|
Perinatal | Strong |
Taxonomic Applicability
Name | Scientific Name | Evidence | Links |
---|---|---|---|
rat | Rattus sp. | Strong | NCBI |
Homo sapiens | Homo sapiens | Strong | NCBI |
Sex Applicability
Sex | Evidence | Links |
---|---|---|
Male | Strong | |
Female | Strong |
Graphical Representation
Overall Assessment of the AOP
Domain of Applicability
Life Stage Applicability,
Taxonomic Applicability,
Sex Applicability
Elaborate on the domains of applicability listed in the summary section above. Specifically, provide the literature supporting, or excluding, certain domains.
Essentiality of the Key Events
Molecular Initiating Event Summary,
Key Event Summary
Provide an overall assessment of the essentiality for the key events in the AOP. Support calls for individual key events can be included in the molecular initiating event, key event, and adverse outcome tables above.
Weight of Evidence Summary
Summary Table
Provide an overall summary of the weight of evidence based on the evaluations of the individual linkages from the Key Event Relationship pages.
Quantitative Considerations
Summary Table
Provide an overall discussion of the quantitative information available for this AOP. Support calls for the individual relationships can be included in the Key Event Relationship table above.